Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT01302912
Other study ID # USZ-OALs-Register
Secondary ID
Status Enrolling by invitation
Phase Phase 4
First received February 23, 2011
Last updated November 3, 2011
Start date February 2011
Est. completion date May 2012

Study information

Verified date November 2011
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: UZurich
Study type Observational

Clinical Trial Summary

Imaging techniques have considerably improved over the last decades and ocular adnexal lymphomas (OALs) nowadays can be detected. As major advances in immunophenotyping and molecular diagnostics in histology have been achieved offering an accurate diagnosis, the investigators would like to introduce that surgical biopsy of an orbital lymphoma becomes crucial for the possibility of a correct diagnosis and proper treatment. As radiotherapy accomplished great preciseness as well and OALs respond excellently to radiation, this therapy should be the treatment of choice in local defined lymphomas instead of blind treatment with steroids. Radiation results in great local control rates of 85% to 100%

- Trial with surgical intervention


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 50
Est. completion date May 2012
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria: - both genders

- >17 years of age

- underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at the University Hospital Zurich, Division of Ophthalmology

- diagnosis histologically proven

Exclusion criteria:

- less than 18 years of age

- patient underwent no MRI before surgery (biopsy)

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Procedure:
Lymphoma-Biopsy
Patients after biopsy of orbital lymphoma

Locations

Country Name City State
Switzerland University Hospital Zurich, Ophthalmic Clinic Zurich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02494700 - Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma Phase 2
Completed NCT01514344 - Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma Phase 2